AVALIAÇÃO DA PRÓPOLIS COMO UM AGENTE TERAPÊUTICO PARA A DOENÇA DE PARKINSON

Abstract

Parkinson's Disease (PD) is characterized by the gradual and more effective destruction of dopaminergic nerve cells in the central nervous system, which influences emotions, mood and the motor system. Most of the drugs used to treat PD result in side effects that are harmful to people with the disease. Given this scenario, this article aims to evaluate the therapeutic potential of propolis in PD, a natural product used for centuries in popular medicine and with many medicinal properties. The importance of the study is highlighted by the increase in life expectancy worldwide, as aging is the most significant risk factor for PD, adding to the fact that the disease does not have a cure and gradually deteriorates the quality of life of its sufferers. . For this purpose, an exploratory and integrative literature review was carried out using the PICO strategy. 23 articles were selected for final analysis after a bibliographic survey of the last 10 years, in the main databases. To this end, the study began with the analysis of the multifactorial and epidemiological etiology of PD, which may be related to oxidative stress, neuroinflammation and mitochondrial abnormalities. Next, a brief description of the traditional treatment of PD and the pharmacological properties of propolis was provided, in addition to a description of its main therapeutic elements, such as flavonoids (CAPE and chrysin). In short, propolis reduced neuronal loss, repeatedly minimized the expression of inflammatory markers, acted as an antioxidant and improved the animals' motor/cognitive scores. Added to these properties is the neuroprotective capacity against excitotoxicity and the formation of glial scars that prevent the reconnection of axons. With the information obtained, it was found that propolis is a potential therapeutic agent for PD, aiming to fill the gaps that current drugs intended for this function do not cover, for example weight loss and cardiovascular and non-motor symptoms.